Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISG-STS 10-01 standard vs histotype-tailored neoadjuvant chemotherapy in high-risk localized adult soft tissue sarcoma
2010-023484-17Phase 3Completed
- Sponsor
- Italian Sarcoma Group
- Start
- Feb 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epirubicin, ifosfamide, gemcitabine, docetaxel, doxorubicin and 2 more in soft tissue sarcoma (STS) (2 arms), sponsored by Italian Sarcoma Group. Primary endpoint: Disease-free survival. Started Feb 2011; status: completed.
02
Drugs
epirubicinifosfamidegemcitabinedocetaxeldoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2010-023484-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023484-17.